SecBot SecBot
6-K ·Filed Jul 15, 2026

ASND

Ascendis Pharma A/S
NEUTRAL
Impact 2/10
Horizonimmediate Processed4mo ago SEC0001193125-26-304903
Notable filing: 6-K
Actionable Insight • Neutral

Routine employee warrant grant with no immediate trading signal. Monitor upcoming quarterly earnings for commercial progress on Skytrofa and Yorvipath, which are the primary value drivers.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$259.80
T+0 close · Jul 15, 2026 · via day close
Latest settled
−11.77%
T+60 · $229.23
Vs SPY
−15.48%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 16 $259.80entry
  2. T+1 · 4mo ago +0.46%α +1.45% · $261.00
  3. T+5 · 4mo ago −2.75%α −1.08% · $252.66
  4. T+20 · 3mo ago −5.22%α −8.84% · $246.23
  5. T+60 · 6w ago −11.77%α −15.48% · $229.23
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Ascendis Pharma filed a 6-K reporting the grant of 14,060 warrants to employees at an exercise price of $265.57 per share, with standard time-based vesting (25% after one year, 75% monthly thereafter). The filing also updates the company's Articles of Association to reflect this grant. This is a routine employee compensation event with no material financial impact.

Key Facts

  • 14,060 warrants granted to employees on July 14, 2026
  • Exercise price of $265.57 per share (closing price on grant date)
  • Warrants vest 25% after one year, remaining 75% over 36 months
  • After this grant, 1,539,503 shares remain available for future warrant grants
  • Articles of Association updated to reflect the grant

Financial Impact

No material financial impact; 14,060 warrants represent a de minimis potential dilution relative to the company's $16.5B market cap

dilution

Risk Factors

  • Potential future dilution from outstanding warrants (4,773,525 outstanding as of this filing)
  • None from this specific filing

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
96% bullish (26 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001193125-26-304903
Document: d109910d6k.htm0001193125-26-304903
Document: 0001193125-26-304903-index-headers.html0001193125-26-304903
Document: 0001193125-26-304903-index.html0001193125-26-304903
Document: 0001193125-26-304903.txt0001193125-26-304903

Track record

41 reports on ASND

Performance horizon

14 of 19 bullish or bearish reports moved the stock their way by T+60. Best: +26.62% at T+20 after the Jun 2, 2026 report. 25 of 27 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $271.96 Now $271.73 −0.08% settles Feb 12
  2. Nov 12, 20264d ago 6-K Neutral 2/10 Entry $275.39 Now $271.73 −1.33% settles Feb 11
  3. Nov 12, 20264d ago 6-K Bullish 6/10 Entry $267.07 Now $271.73 +1.74% settles Feb 10
  4. Nov 12, 20264d ago Press Release Neutral 5/10 Entry $267.07 Now $271.73 +1.74% settles Feb 10
  5. Nov 6, 202610d ago 6-K Bullish 6/10 Entry $259.85 Now $271.73 +4.57% settles Feb 5
  6. Nov 6, 202610d ago Press Release Bullish 6/10 Entry $256.82 Now $271.73 +5.81% settles Feb 4
  7. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $253.45 Now $271.73 +7.21% settles Feb 3
  8. Nov 2, 202614d ago Institutional Cluster Bullish 4/10 Entry $250.17 Now $271.73 +8.62% settles Feb 1
  9. Oct 26, 202621d ago 6-K Bullish 5/10 Entry $245.85 Now $271.73 +10.53% settles Jan 25
  10. Oct 16, 20264w ago 6-K Bullish 7/10 Entry $225.25 Now $271.73 +20.63% settles Jan 13
Showing 10 of 41

US Market Status

Market Closed · Opens Wed (10h 53m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 15, 2026